Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11485426 | 0.85 | CYP2A6 (0.58) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL5543495 | 0.82 | AKR1B1 (0.38) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL16414423 | 0.82 | AKR1B1 (0.38) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL2080656 | 0.79 | AKR1B1 (0.40) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL5542366 | 0.79 | AKR1B1 (0.36) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL2786069 | 0.79 | HSP90AA1 (0.45) | CYP2A6AKR1B1LOXL2ASIC3 | |
| SCHEMBL12644311 | 0.79 | CYP2A6 (0.42) | CYP2A6LOXL2ASIC3 | |
| SCHEMBL5540135 | 0.78 | AKR1B1 (0.36) | CYP2A6AKR1B1HDAC6LOXL2ASIC3 | |
| SCHEMBL2094705 | 0.78 | AKR1B1 (0.41) | CYP2A6AKR1B1HDAC6LOXL2CHRNA7 | |
| SCHEMBL2056139 | 0.78 | AKR1B1 (0.39) | CYP2A6AKR1B1LOXL2ASIC3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | CYP2A6 533/4885AKR1B1 2158/4885HDAC6 176/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | CYP2A6 1156/4885AKR1B1 3587/4885HDAC6 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.